Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

443 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.
Englund JA, Karron RA, Cunningham CK, Larussa P, Melvin A, Yogev R, Handelsman E, Siberry GK, Thumar B, Schappell E, Bull CV, Chu HY, Schaap-Nutt A, Buchholz U, Collins PL, Schmidt AC; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1096 Study Group. Englund JA, et al. Among authors: collins pl. Vaccine. 2013 Nov 19;31(48):5706-12. doi: 10.1016/j.vaccine.2013.09.046. Epub 2013 Oct 5. Vaccine. 2013. PMID: 24103895 Free PMC article. Clinical Trial.
Live viral vaccines for respiratory and enteric tract diseases.
Chanock RM, Murphy BR, Collins PL, Coelingh KV, Olmsted RA, Snyder MH, Spriggs MK, Prince GA, Moss B, Flores J, et al. Chanock RM, et al. Among authors: collins pl. Vaccine. 1988 Apr;6(2):129-33. doi: 10.1016/s0264-410x(88)80014-8. Vaccine. 1988. PMID: 2838984 Review.
Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity.
Whitehead SS, Firestone CY, Karron RA, Crowe JE Jr, Elkins WR, Collins PL, Murphy BR. Whitehead SS, et al. Among authors: collins pl. J Virol. 1999 Feb;73(2):871-7. doi: 10.1128/JVI.73.2.871-877.1999. J Virol. 1999. PMID: 9882287 Free PMC article. Clinical Trial.
A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge.
Tao T, Skiadopoulos MH, Durbin AP, Davoodi F, Collins PL, Murphy BR. Tao T, et al. Among authors: collins pl. Vaccine. 1999 Mar 5;17(9-10):1100-8. doi: 10.1016/s0264-410x(98)00327-2. Vaccine. 1999. PMID: 10195620
This was used to recover a fully-viable, recombinant chimeric PIV3-PIV1 virus, termed rPIV3-1, which bears the major protective antigens of PIV1 and is wild type-like with regard to growth in cell culture and in hamsters [Tao T, Durbin AP, Whitehead SS, Davoodi F, Collins …
This was used to recover a fully-viable, recombinant chimeric PIV3-PIV1 virus, termed rPIV3-1, which bears the major protective antigens of …
A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
Tao T, Davoodi F, Cho CJ, Skiadopoulos MH, Durbin AP, Collins PL, Murphy BR. Tao T, et al. Among authors: collins pl. Vaccine. 2000 Jan 31;18(14):1359-66. doi: 10.1016/s0264-410x(99)00406-5. Vaccine. 2000. PMID: 10618533
443 results